Gastrointestinal Therapeutics Market Size & Share, by Route of Administration (Oral, Injectable); Distribution Channel; Drug Class - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2034

Gastrointestinal Therapeutics Market - Regional Analysis

North America Market Insights

North America is considered the dominant region in the gastrointestinal therapeutics market, projected to garner the largest share of 42.2% by the end of 2034. The market’s growth in the region is subject to an increase in the disease occurrence as well as the existence of innovative health and medical infrastructure. In addition, the region’s 6.6% growth rate is also reflecting a surge in the incorporation of biosimilars and biologics, wherein IBD is affecting more than 3.2 million people. Besides, single-payer system in Canada provides a wide-range accessibility, while progression in the U.S. has led to drug development, catering to almost 63% of the international GI clinical trials.

The market in the U.S. is significantly growing, with an expected 90% of the region’s market, which is driven by an estimated 17% increase in Medicare GI drug expenditure since 2020. Besides, biosimilar competition has diminished anti-TNF expenses by almost 42%, resulting in the extended accessibility to at least 2.5 million patients in the country. Meanwhile, the CDC has reported that approximately 26 million GERD incidences takes place every year, attributing to PPI usability, despite the existence of FDA safety guidelines, thus enhancing the market demand in the country.

The gastrointestinal therapeutics market in Canada is also growing at a 6.1% rate, with provincial reforms covering almost 95% of required biologics. British Columbia’s biosimilar mandate has saved almost USD 98 million yearly since previous years, while Ontario has enhanced GI treatment service funding by at least 20% between 2021 and 2024. Besides, the federal government in the country has made the provision of USD 1.3 billion for GI drugs as of 2023, with an extreme focus on telehealth expansion in rural areas. Meanwhile, the country’s unusual position includes serving as an evaluation ground for cost-containment initiatives, thereby suitable for market upliftment.

North America Gastrointestinal Therapeutics Supply Chain & Trade Facilities (2021–2025)

APAC Market Insights

Asia Pacific in the gastrointestinal therapeutics market is the fastest-growing region, with an anticipated 22.3% of the revenue share during the forecast duration, along with a growth of 8.3%. The market’s development in the region is highly fueled by a rise in the biologic integration and GERD/IBD occurrence. China is deliberately dominating the region, owing to AI implementation in healthcare services, while the biosimilar expansion in India is readily diminishing expenses. The existence of fast-track acceptances in South Korea has lowered delays in launch to at least 3.5 months, thereby positively impacting the overall market growth.

The gastrointestinal therapeutics sector in China is gaining increased traction, with a projected growth of USD 18 billion by the end of the forecast timeline, further accounting for 50% of the region’s revenue. This is effectively attributed to the presence of government-based health policies, along with an increase in the patient pool. Besides, the NMPA has reported that there has been a surge in IBD patients by 1.9 million as of 2024, of which a significant growth has been observed for biologics by 25%, owing to an expansion in national insurance coverage. In this regard, volume-specific procurement policies have reduced biologic expenses by 55%, thereby uplifting the market in the country.

The gastrointestinal therapeutics market in India is also expected to grow with a valuation of USD 2.7 billion during the forecast duration, which is highly driven by more than 26 million GERD cases, along with biosimilar integration. Based on this, CDSCO’s biosimilar acceptances in 2024 have diminished treatment expenses by almost 65%, with Biocon’s trastuzumab garnering approximately 18% of the regional market share. Besides, the government’s 345 billion program enhancement to over 450 hospitals in the country has aimed to augment accessibility, thus skyrocketing the market exposure.

APAC Government Initiatives in Gastrointestinal Therapeutics (2021–2025)

Europe Market Insights

Europe is considered to hold a considerable share of 28.1% in the gastrointestinal therapeutics market during the forecast period, along with a 5.5% growth rate, which is expected to reach €43 billion. The market’s upliftment in the region is fueled by biosimilar incorporation and an upsurge in the aging population. Germany is leading the region with the maximum share, which is attributed to GI drugs spending and universal health coverage solutions. This is followed by the UK, with the provision of the NHS budget plan for GI therapies that includes IBD biologics. Besides, the budget for customized medicine in France and telemedicine adoption in Spain is also bolstering the market in the region.

The gastrointestinal therapeutics industry in Germany is projected to grow with a 30.5% revenue share, accounting for € 12.8 billion by the end of 2034, which is attributed to an increase in biosimilar integration and the existence of strong healthcare facilities. The Federal Ministry of Health in the country has revealed that there has been € 4.7 billion yearly spending on GI drugs, of which 70% caters to anti-TNF prescriptions. Besides, policies such as GKV’s mandatory substitution have lowered biologic expenses by almost 35%, while R&D in the private sector has fueled innovation, thus suitable for market growth.

The gastrointestinal therapeutics market in the UK is anticipated to hold 24% of the region’s market share, accounting for £ 8.5 billion by 2034. This is readily supported by NHS biologics funding, along with NICE’s escalated acceptances. For instance, almost 8.2% of the NHS budget, which is £ 525 million, was offered to GI therapies in 2024, which covered 92% of critical IBD cases. Besides, biosimilars, such as Celltrion’s Remsima, have diminished expenses by 50%, with telemedicine services managing 48% of consultations, thereby creating an optimistic market outlook.